Cuantificación de niveles de hormona estimulante de la tiroides (TSH) en pacientes con diabetes mellitus tipo 2 en el Hospital Santa Inés en el período de abril 2022 – mayo 2023

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a chronic, metabolic disease due to the presence of hyperglycemia. In 2015, the worldwide prevalence of T2DM was 9.1%, approximately 415 million adults. Thyroid dysfunction is an impairment in the secretion of thyroid hormones. It presents clinically as subclinical hyperthyroidism or hypothyroidism. Outcomes: To determine the level of thyroid-stimulating hormone (TSH), clinical and epidemiological characteristics in patients with T2DM in the Hospital Santa Inés of Cuenca from April 2022 to May 2023. Methods: Cross-sectional descriptive study. In a population of 95 patients with T2DM, a form was used to collect sociodemographic, clinical, and laboratory data from medical records in patients with T2DM who attended the endocrinology outpatient clinic. Results: The serum TSH level in patients with T2DM was a median of 2.44 (IQR: 1.62 – 3.28) mUI/L. The 94.74% (90) patients corresponded to an age between 40 and 65 years old. The median time of T2DM evolution was 5 years. The most frequent comorbidity was dyslipidemia in 35.79% of the population, followed by arterial hypertension with 37.89%, and 2 patients with chronic renal failure. Conclusion: Patients with T2DM had a median serum TSH level of 2.44 mUI/L. The cohort was predominantly female, with an age group between 40 and 65 years old, and a median time of evolution of T2DM of 5 years. The most common thyroid dysfunction found was subclinical hypothyroidism in 14 patients